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Plasma FGF21 levels and hepatic FGF21 gene
expression increase dramatically after birth in mice.
This induction is initiated by suckling, requires lipid
intake, is impaired in PPARa null neonates, and is
mimicked by treatment with the PPARa activator,
Wy14,643. Neonates exhibit reduced FGF21 expres-
sion in response to fasting, in contrast to the upregu-
lation occurring in adults. Changes in FGF21 expres-
sion due to suckling or nutritional manipulations
were associated with circulating free fatty acid and
ketone body levels. We mimicked the FGF21 post-
natal rise by injecting FGF21 into fasting neonates,
and found that this enhanced the expression of
genes involved in thermogenesis within brown fat,
and increased body temperature. Brown adipocytes
treated with FGF21 exhibited increased expression
of thermogenic genes, higher total and uncoupled
respiration, and enhanced glucose oxidation. We
propose that the induction of FGF21 production by
the liver mediates direct activation of brown fat ther-
mogenesis during the fetal-to-neonatal transition.
INTRODUCTION
Fibroblast growth factor 21 (FGF21), amember of the FGF super-
family, has recently emerged as a novel regulator of metabolism
(Kharitonenkov et al., 2005). FGF21 is mainly produced by the
liver and is induced after fasting in both rodents and humans
(Inagaki et al., 2007; Badman et al., 2007; Ga¨lman et al., 2008).
Consistent with its proposed role as a regulator of the metabolic
adaptations to fasting (Reitman, 2007), FGF21 causes paracrine
effects, such as induction of hepatic ketogenesis, and endocrine
actions, such as the promotion of lipolysis in white adipose
tissue (Inagaki et al., 2007; Badman et al., 2007), although this
last effect is controversial (Arner et al., 2008). Moreover, in rodent
models, FGF21 corrects metabolic disorders of obese and dia-
betic mice, inhibiting hepatic lipogenesis and glucose produc-
tion (Berglund et al., 2009; Coskun et al., 2008; Xu et al., 2009).
FGF21 has also been reported to promote glucose uptake by
white adipocytes (Kharitonenkov et al., 2005).206 Cell Metabolism 11, 206–212, March 3, 2010 ª2010 Elsevier Inc.PPARa has amajor role in the control of FGF21 expression and
release by the liver (Badman et al., 2007; Inagaki et al., 2007);
accordingly, treatment with fibrates increases FGF21 expression
(Ga¨lman et al., 2008). Free fatty acids appear to be major regula-
tors of FGF21 expression, acting via PPARa-dependent activa-
tion of the FGF21 gene (Mai et al., 2009). This effect of fatty acids
may explain not only the induction of FGF21 gene expression
after fasting but also the paradoxically high levels of FGF21
reported recently in patients with type II diabetes and obesity
(Chavez et al., 2009; Zhang et al., 2008).
Metabolic adaptations have key roles in development. Major
metabolic changes take place rapidly in the transition from fetal
life, characterized by the predominant utilization of glucose as
a metabolic fuel, to postnatal life, when the use of lipids from
milk predominates. With birth comes a sudden need to sustain
physical muscle activity and thermogenesis. The first appear-
ance of these physiological processes in the neonate is associ-
ated with a marked increase in energy metabolic activity, and,
for instance, postnatal brown fat nonshivering thermogenesis
requires a high metabolic fuel oxidation. These metabolic adap-
tations are accomplished by the coordinate regulation of expres-
sion of genes encoding components of the metabolic fuel oxida-
tion machinery. PPARa, in particular, promotes the concerted
expression of genes encoding lipid oxidative pathway compo-
nents that mediate fatty acid catabolism and ketogesis, which
are required for neonates to cope with the sudden availability
of large amounts of fatty acids from milk (Yubero et al., 2004).
Alterations in metabolism that occur during the perinatal period
have long-term consequences in adulthood and influence the
risks for development of obesity and type II diabetes (Levin,
2006). Thus, identifying the molecular actors that control these
processes is not only essential for understanding neonatal meta-
bolic pathophysiology but can also be expected to provide key
insights into permanent metabolic alterations in adults. An anal-
ysis of the developmental regulation of FGF21 and the potential
involvement of FGF21 in neonatal metabolic adaptations are the
focus of the present study.
RESULTS
FGF21 Expression Is Induced after Birth
and Is Regulated by Diet Composition at Weaning
FGF21 levels in fetal plasma were very low (Figure 1A). After
birth, plasma FGF21 levels increase rapidly, surpassing those
Figure 1. Developmental Regulation of FGF21 Gene Expression:
FGF21 Gene Expression in the Liver Is Induced and Plasma FGF21
Levels Are Increased at Birth
Plasma FGF21 levels (A) and FGF21 mRNA levels in liver (B) at the indicated
times during neonatal development. HC and HF denote mice spontaneously
weaned onto a high-carbohydrate (HC) or high-fat (HF) diet between days
15 and 21. Bars are means ± SEM of three to six individual samples from sepa-
rate litters. Statistically significant differences (p < 0.05) with respect to fetuses
are denoted by *, and those with respect to adults by #.
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remained high in 6-day-old mice and declined thereafter. At
3 weeks, the time at which weaning has been completed,
FGF21 levels were similar to those in adults.
In fetal liver and in newborn mice at birth (before initiation of
suckling), FGF21 mRNA levels were very low (Figure 1B).
FGF21 mRNA levels were induced soon thereafter, reaching
levels similar to those in the adult liver within 16 hr. FGF21
mRNA levels during postnatal development were maximal in
6-day-old pups and were markedly reduced in the livers of
21-day-old mice compared with those from 15-day-old pups.
Spontaneous weaning occurs in mice between neonatal days
15 and 21, when there is a progressive shift from a lipid-based
diet (milk) to a mainly carbohydrate-based diet (regular chow).
In mice provided access to a high-fat diet instead of the regular
chow diet from day 15 onward, liver FGF21 mRNA levels were
not reduced between day 15 and day 21 and were much higher
than in 21-day-old mice weaned on the regular, high-carbohy-
drate diet.
Food Intake Is Required for the Induction of FGF21Gene
Expression at Birth, an Effect Mediated by Lipid Intake
To investigate the mechanisms that elicit the increase in FGF21
gene expression at birth, we determined the effects of blunting
the initiation of suckling. Figure 2A shows that postnatal feeding
is an absolute requirement for FGF21 gene induction; pups thatCewere not allowed to suckle showed no induction of FGF21mRNA
expression, indicating that milk intake induced the expression of
the FGF21 gene. The components of food intake that stimulated
FGF21 gene expression were assessed by feeding nonsuckling
pups a lipid emulsion or a glucose solution by intragastric
gavage. Lipid intake mimicked the action of milk on FGF21
expression, whereas glucose intake had no effect (Figure 2A).
Injection of b-hydroxybutyrate to fasted pups did not modify
significantly hepatic FGF21 mRNA expression (86% ± 18%
respect to control levels).
PPARa Is Required for FGF21 Gene Induction at Birth
To assess whether activation of PPARa could mediate the action
of milk lipids on the FGF21 gene, we studied PPARa null pups
(Figure 2B). Expression of FGF21 mRNA at birth in the liver of
PPARa null mice was lower than in wild-type littermates. More-
over, postnatal induction of the FGF21 gene mediated by milk
intake was completely suppressed in PPARa null pups. In wild-
type pups starved after birth, injection of the PPARa activator
Wy14,643 induced a significant increase in liver FGF21 mRNA
levels, whereas there was no such response in PPARa null
pups. The lack of PPARa caused a significant reduction in
plasma FGF21 levels in neonates (Figure 2B).
FGF21mRNALevels in Liver andFGF21 Levels in Plasma
Are Not Increased by Fasting during Early Stages
of Development
Fasting caused a marked increase in FGF21 mRNA levels in the
livers of 21-day-old pups and adult mice (Figure 2C). In contrast,
FGF21 mRNA abundance decreased markedly in the livers of
fasted 2-day-old pups and more modestly in fasted 6-day-old
pups. When 21-day-old pups had been undernourished (over-
sized litters), white adipose tissue development was delayed
(i.e., 62% ± 15% reduction in the weight of gonadal fat with
respect to 21-day-old control pups, p < 0.05), and the induction
of hepatic FGF21 mRNA expression by fasting was blunted.
Plasma FGF21 levels were significantly increased in fasted
adults, although to a much lesser extent than the increase in
hepatic FGF21 mRNA levels. In contrast, fasting of 2-day-old
pups results in the opposite response: a dramatic reduction in
FGF21 plasma levels (Figure 2C, right).
Free Fatty Acid and b-Hydroxybutyrate Levels
in the Plasma of Fetal, Newborn, and Adult Mice under
Different Nutritional Regimens
A parallel assessment of free fatty acids levels in plasma was
performed (see Table S1 available online). Fetal and newborn
mice at birth showed very low levels of free fatty acids in plasma.
There was a marked increase in circulating free fatty acids 16 hr
after birth in suckling pups, but not in pups not allowed to suckle.
When nonsuckling pups were administered a lipid emulsion, free
fatty acid levels were increased to levels similar to those found in
fed pups. There were no significant alterations in free fatty acid
levels in PPARa null neonates. Once pups had begun suckling,
starvation had differential effects on free fatty acids that
depended on the stage of development. In 21-day-old and adult
mice, fasting caused an increase in plasma free fatty acids
but had no effect in 6-day-old mice, and it even caused a
decrease in 2-day-old pups. However, fasting of undernourishedll Metabolism 11, 206–212, March 3, 2010 ª2010 Elsevier Inc. 207
Figure 2. Effects of Postnatal Starvation,
Lipid or Glucose Intake, and PPARa Abro-
gation on the Neonatal Induction of FGF21
Gene Expression in the Liver
(A) FGF21mRNA levels in the livers of mice at birth
(prior to suckling), of pups at 8 or 16 hr of life that
were allowed to suckle (fed) or not allowed to
suckle (fasted), and of fasted pups who received
a lipid emulsion or glucose after birth.
(B) FGF21 levels in plasma and FGF21 mRNA
levels in the livers of wild-type and PPARa null
neonates. Pups were analyzed at birth, 16 hr after
birth (fed and fasted), and after injection with
Wy14,643 after birth.
(C) Effects of a 24 hr fast on FGF21 mRNA expres-
sion and plasma FGF21 levels in mice at distinct
stages of development. UD, undernourished
21-day-old pups belonging to oversized litters
(18 pups/litter). Bars are the means ± SEM of
FGF21 mRNA levels, which are expressed as rela-
tive to the values in pups at birth (A and B, left) or
relative to fasted 2-day-old pups (C, left). The bars
in (B) (right) and (C) (right) are the means ± SEM of
plasma FGF21 levels. Data are the means of four
to six individual littermates obtained from four to
six litters. Statistically significant differences (p <
0.05), with respect to values at birth, are denoted
by * (A and B). Differences between fed and fasted
mice are denoted by # (A and C), and those
between PPARa null and wild-type littermates
are denoted by # (B).
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21-day-old mice weaned on a high-fat diet, free fatty acid levels
were greater than in mice weaned on the regular, high-carbohy-
drate diet.
Plasma b-hydroxybutyrate levels were very low in fetuses
(Table S2) but increased suddenly after initiation of suckling.
In contrast, plasma b-hydroxybutyrate levels were significantly
lower in PPARa null neonates. Although fasting caused amarked
induction of plasma b-hydroxybutyrate levels in wild-type adults,
the induction was much more moderate in young (6-day-old)
pups.
FGF21 Causes Thermogenic Activation of Brown
Adipose Tissue in Neonatal Mice and Cultured Brown
Adipocytes
The expression of genes related to thermogenic activation is
increased in neonatal brown adipose tissue (BAT) after birth
(Figure 3A), in parallel with the rise in plasma levels of FGF21.
To assess the potential effects of the postnatal burst in circu-
lating FGF21 in response to the initiation of suckling, neonatal
mice were treated 4 hr after birth with a single dose of recombi-
nant mouse FGF21. The mice were not allowed to suckle further
and were analyzed 5, 12, and 18 hr later. Treatment with FGF21
(12 hr) caused a mild, but statistically significant, reduction in
blood glucose (25 ± 4.4 mM in FGF21-treated mice versus
39 ± 6 mM in controls, p < 0.05) and did not significantly modify
the levels of free fatty acids (0.26 ± 0.05 mM in FGF21-treated
mice versus 0.27 ± 0.03 mM in controls) or b-hydroxybutyrate
(0.54 ± 0.14 mM in FGF21-treated versus 0.64 ± 0.06 mM in
controls). FGF21 significantly induced the mRNA expression of
genes encoding proteins involved in mitochondrial oxidation208 Cell Metabolism 11, 206–212, March 3, 2010 ª2010 Elsevier Inc.and BAT thermogenic activation (e.g., PGC-1a, UCP1, 50-deiodi-
nase-2 [Dio2], cytochrome c [Cyt c], and the hormone-sensitive
lipase [HSL]), with specific time courses of induction for the
distinct genes (Figure 3C). We also noted a significant increase
in the expression of the mRNA for the glucose transporters
GLUT1 and GLUT4. Other genes related to fatty acid oxidation
(e.g., medium-chain acyl-CoA dehydrogenase [MCAD] and
carnitine palmitoyltransferase-II [CPTII]) or overall adipogenic
differentiation (e.g., fatty acid binding protein-4 [FABP4] and
glycerol-3-phosphate dehydrogenase [GPDH]) were not altered.
PGC-1a, UCP1, andCyt c protein levels in BATwere significantly
induced by FGF21 (Figure 3B). Body temperature of pups,
recorded as skin temperature in the dorsal area, was significantly
higher after FGF21 treatment (Figure 3D). Moreover, PPARa null
pups exhibited a reduced postnatal induction of thermogenic
genes after birth, which was rescued when PPARa null pups
were treated with FGF21 just after birth (Figure 3E, left). Parallel
results were obtained when body temperature was recorded in
PPARa null pups treated with FGF21 (Figure 3E, right).
In the liver, the mRNA expression of Cyt c and PGC-1a was
significantly induced 12 hr after FGF21 injection (see Fig-
ure S1A). We noted no significant changes in the expression of
phosphoenolpyruvate carboxykinase (PEPCK), which is indica-
tive of gluconeogenesis; hydroxymethyl glutaryl-CoA synthase-
2 (HMGCS), a key enzyme of ketogenesis; and MCAD, CPTII,
and GLUT1, at any time of FGF21 treatment. Skeletal muscle
and heart did not exhibit significant changes in the expression
of any of the genes analyzed in response to FGF21 (see
Figure S1B).
To assess whether FGF21 may act directly on BAT, mouse
brown adipocytes were differentiated in culture and were then
Figure 3. Gene Expression in Neonatal Mouse BAT, Effects of FGF21 Injection on Neonatal BAT, and Effects of FGF21 on Brown Adipocytes
in Primary Culture
(A) Transcript levels of thermogenic genes in BAT from pups at birth (0 hr) and at the indicated time after birth.
(B–D) Pups were injected 4 hr after birth with FGF21, and BAT was studied at the indicated times after injection. Representative immunoblots for PGC-1a and
UCP1 are shown in (B), left. Levels of PGC-1a, UCP1, and Cyt c proteins are shown in (B), right. (D) Neonatal body temperature 12 hr after FGF21 injection.
(E) Transcript levels of PGC-1a and UCP1 (left) and body temperature (right) in PPARa null pups and wild-type littermates.
(F) Transcript levels of the indicated genes in differentiated brown adipocytes in culture treated with FGF21.
(G andH) Differentiated brown adipocytes in culture were treatedwith 5 nMFGF21 or saline for 24 hr; (G), total respiration and uncoupled respiration; (H), 14C-CO2
dpm levels after 3 hr incubation with 14C-glucose of control and FGF21-treated brown adipocytes. Bars are means ± SEM of five to seven pups or independent
cell cultures. Statistically significant differences (p < 0.05) between controls and FGF21-treated conditions are denoted by *. In (E), statistically significant differ-
ences (p < 0.05) between PPARa null pups and wild-type littermates for the same experimental condition are shown as #, and those between 0 and 16 hr are
shown as +.
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Neonatal Induction of FGF21 Activates Brown Fatexposed to FGF21. Our results indicated that 5 nM FGF21
significantly induced the expression of the genes encoding
proteins involved in thermogenic activation (PGC-1a, UCP1,
GLUT4, Cyt c), whereas a higher concentration of FGF21 (50 nM)
did not further enhance these effects (data not shown). The
expression of FABP4 did not change. To determine directly
the action of FGF21 on thermogenic function in brown adipo-
cytes, total and uncoupled cell respiration was studied. FGF21
caused a 41% increase in brown adipocyte oxygen consump-
tion. Moreover, the uncoupled (oligomycin-resistant) respiration
was induced by FGF21 treatment (64% induction) (Figure 3G).
FGF21 caused also a significant induction (around 3-fold) of
glucose oxidation in brown adipocytes (Figure 3H).
DISCUSSION
The present findings provide the first characterization of the
developmental regulation of FGF21 expression in mice, showing
that circulating levels of FGF21 aremarkedly induced in the post-
natal period, increasing from very low levels in the fetus to
maximum levels just a few days after birth. A similar pattern
was observed for hepatic FGF21 gene expression, consistent
with a major role for the liver in the systemic production of
FGF21. Previous studies have shown that physiological situa-
tions that lead to large changes in liver FGF21 gene expression,
such as starvation or a ketogenic diet in adults, are usually asso-
ciated with moderate changes in circulating FGF21 levels
(Badman et al., 2007; and present results). The present results
indicate that initiation of suckling not only profoundly modifies
FGF21 gene expression in the liver but also results in a massive
increase in plasma FGF21 levels.
The findings that initiation of food intake at birth is the trigger
that activates FGF21 gene transcription and that FGF21 induc-
tion is blocked by postnatal food deprivation indicate that the
response of neonates to starvation is opposite to that of adults,
where FGF21 gene expression is activated by starvation. In neo-
nates, high levels of free fatty acids appear following the initiation
of suckling due to the high lipid content of milk. If suckling is
prevented, blood free fatty acid levels remain low in neonates
rather than increasing as they do in adults (Brun et al., 1999;
and present data); this reflects the scarcity of white fat deposits
at this stage of development that would otherwise lead to an
increase in fatty acids through lipolysis of stored fat. Taken
together with recent reports on a direct effect of fatty acids on
FGF21 gene expression in adults (Mai et al., 2009), these findings
support the notion that fatty acids are the key regulators of the
FGF21 gene. This is also consistent with the fact that PPARa,
which is known to be activated by fatty acid-related metabolites,
was absolutely required for the induction of FGF21 gene expres-
sion in response to the initiation of suckling. Moreover, the shift in
the response to starvation, from FGF21 gene repression to
FGF21 gene activation, between postnatal days 2 and 21 is
also consistent with this scenario. By day 21 after birth, substan-
tial amounts of white adipose tissue have developed; at this
point, fasting can therefore effectively increase circulating free
fatty acid levels through the activation of lipolysis. When white
fat development was delayed due to postnatal undernutrition,
the induction of FGF21 gene expression was blunted. The main-
tenance of high levels of FGF21 gene expression in mice that are210 Cell Metabolism 11, 206–212, March 3, 2010 ª2010 Elsevier Inc.weaned onto a high-fat diet (fat content similar to milk) instead of
onto a high-carbohydrate diet indicates that fatty acids from diet
can also increase liver FGF21 gene expression beyond the
immediate postnatal period. Collectively, these results indicate
that hepatic FGF21 gene expression during development is
under the control of fatty acids that reach the liver. This is true
regardless of the origin of fatty acids, be it food or endogenous
lipolysis in white fat. In this sense, the extent of white adipose
tissue development appears to be a major determinant of the
regulation of FGF21 gene expression in the liver.
The changes in FGF21 gene expression studied here not only
parallel changes in plasma free fatty acids but also ketone body
levels. For example, ketogenesis is activated spontaneously in
newborns in response tomilk intake, but not to starvation (Yubero
et al., 2004). Thedatapresentedhere support theproposition that
FGF21 induction is associated with ketogenic states—in this
case, that associated with initiation of lipid intake after birth.
The increase in FGF21 gene expression at birth suggests that
FGF21 plays an important role in the metabolic adaptations that
occur during the shift from fetal to neonatal metabolism. When
we mimicked the postnatal burst in FGF21 levels that occur in
fed pups by injecting FGF21 into fasted pups, we observed
a coordinate induction of genes related to thermogenic activa-
tion and glucose utilization in BAT as well an increase in body
temperature. Increased glucose utilization may contribute to
the ability of FGF21 treatment to lower blood glucose levels in
neonates. Although postnatal thermal stress is themain determi-
nant of BAT thermogenic activation after birth, food intake is also
required (R.I., unpublished data). Our present data strongly
support the notion that FGF21 may be a food intake-dependent
signal that favors neonatal BAT thermogenic activation. The
impaired expression of thermogenic genes in BAT from pups
lacking PPARa—and, therefore, exhibiting low plasma FGF21
levels—and the restoration of thermogenic gene expression
and body temperature by exogenous FGF21 further support
the role of the FGF21 released by liver in the control of neonatal
BAT thermogenic activity.
Although we cannot exclude the possibility that FGF21 exerts
indirect effects on thermogenic activation within BAT (i.e., by
influencing sympathetic activation), our results in cultured brown
adipocytes strongly support the notion that FGF21 acts directly
on BAT. At birth, BAT expresses b-Klotho, an essential cofactor
required for FGF21 action (Ito et al., 2000). The present findings
raise questions as to whether FGF21 also acts as an activator
of BAT thermogenesis in adults. Changes in the microscopy
morphology of BAT in adult transgenic mice that overexpress
FGF21 are consistent with enhanced activation (Kharitonenkov
et al., 2005), and chronic treatment of micewith FGF21 increases
the expression of UCP1 and Dio2 (Coskun et al., 2008) and
glucose uptake (Xu et al., 2009) in BAT. However, in certain situ-
ations (e.g., when FGF21 levels increase during adult starvation),
the positive effects of FGF21 on BAT thermogenic activation
would hardly be compatible with the known reduction in thermo-
genic BAT activity. Research on these issues is currently
underway.
Paracrine actions of the induction of FGF21 expression in
postnatal liver may also take place. FGF21-induced PGC-1a
gene expression in neonatal liver is consistent with recent data
in FGF21-treated adult mice (Potthoff et al., 2009); however,
Figure 4. Schematic Representation of the Regulation of FGF21
Gene Expression and FGF21 Effects during the Transition from Fetal
to Neonatal Metabolism
Transcription of the FGF21 gene in the liver and release of FGF21 into the
circulation are induced immediately after birth in response to the high fatty
acid availability associated with the initiation of suckling. PPARa mediates
the milk ingestion-dependent induction of FGF21 expression at birth. The
burst in FGF21 levels after birth exerts endocrine actions that are relevant to
metabolic adaptations in the neonatal period, mainly the induction of thermo-
genesis in BAT.
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observed effect of FGF21 reducing blood glucose in neonates
and lack of effect on the PEPCK gene. With regards to ketogen-
esis, the injection of FGF21 did not modify either circulating
ketone bodies or the expression of key genes of ketogenesis in
neonates. The starved condition of FGF21-treated pups may
not allow for the enhancement of ketogenesis, a process that
is completely associated with milk consumption in the neonatal
period (Yubero et al., 2004).
In summary, hepatic FGF21 gene expression and FGF21
levels in blood are developmentally regulated by nutritional
determinants associated with fat availability in the liver, including
the initiation ofmilk intake and a fat-enriched diet versus a carbo-
hydrate-rich diet (Figure 4). The relationship between FGF21
expression, fatty acid availability, and ketogenesis during post-
natal development, a physiological situation that is completely
distinct from starvation in adults, suggests that FGF21 has
a conserved functional role in the mediation of paracrine and
endocrine metabolic adaptations to high fatty acid availability
in the liver. Moreover, our data indicate that FGF21 specifically
targets BAT thermogenic activation in neonates and indicate
that FGF21 released by the liver may be a novel key signal
contributing to neonatal activation of BAT thermogenesis in
response to the initiation of milk intake.EXPERIMENTAL PROCEDURES
Mice were used in accordance with Directive 86/609/EEC. For studies in
fetuses, cesarean sections were performed on Swiss mice on day 19 of gesta-Cetion. Pups were studied starting at the time at which all pups had been born but
had not yet started suckling (0 hr) and at the indicated times after birth. Adult
mice were 3 months old. For studies on postnatal starvation, pups were sepa-
rated from mothers prior to initiation of suckling, and placed in a humidified
thermostatically controlled chamber (30C). Pups were administered 100 ml
of a triacylglycerol emulsion (Intralipid, Pharmacia) or 100 ml of a 0.3 g/ml
glucose solution, by intragastric gavage. When indicated, pups were injected
intraperitoneally 2 hr after birth with 50 mgWy14,643 (Sigma)/g body weight, or
b-hydroxybutyrate (0.1 mg/g body weight) and were studied 14 hr later.
Heterozygote mice (129S4/SvJae-Pparatm1Gonz/J) were mated and experi-
ments were performed on PPARa null pups and wild-type littermates. For
studies on starvation at distinct stages of development, mice were fasted for
24 hr. The high-fat diet used was from Harlan Teklad (percent of total gross
energy is as follows: 36% carbohydrate, 42% fat, 22% protein). For postnatal
undernutrition, pups were adjusted to oversized litters (18 pups) from birth to
day 21. To study the effects of FGF21, pups were intraperitoneally injected
with saline (vehicle) or 2.5 mg mouse FGF21 (Phoenix Pharmaceuticals)/g of
body weight 4 hr after birth. Pups were not allowed to suckle thereafter and
were examined 5, 12, and 18 hr after the injection. A KM-1420 temperature
recorder (Kane-May Measuring Instruments, UK) was attached to the dorsal
skin area of pups for assessment of body temperature. Mice were killed by
decapitation. Liver, interscapular BAT, leg skeletal muscle, and heart were
dissected. Brown adipocytes were differentiated in primary culture as previ-
ously reported (Carmona et al., 2005). FGF21 (5 or 50 nM) was added to differ-
entiated brown adipocytes (day 8 of culture), and cells were harvested 5 or
24 hr later. RNA was extracted (RNeasy, QIAGEN) and transcript levels were
determined by quantitative RT-PCR using TaqMan Assay-on-demand probes
(see the Supplemental Experimental Procedures) and the ABI/Prism 7700
Detector System (Applied Biosystems). The mean value of sample duplicates
was normalized to that of the 18S rRNA gene using the comparative (2DCT)
method. Oxygen consumption of brown adipocytes was recorded using the
Oxygen Biosensor System (BD) (see the Supplemental Experimental Proce-
dures) in the absence or presence (uncoupled respiration) of 10 mg/ml oligomy-
cin. Glucose oxidation was determined by the assessment of 14CO2 produc-
tion from 14C-glucose added to cell culture medium 24 hr after 5 nM FGF21
treatment (see the Supplemental Experimental Procedures). FGF21 levels in
plasma were determined by ELISA (Phoenix Secretomics). Immunoblot of
PGC-1a and UCP1 in BAT extracts was performed as reported (Carmona
et al., 2005; Yubero et al., 2004), whereas Cyt c was determined by ELISA
(MitoSciences). Blood glucose levels were determined using Accutrend
(Roche), and plasma nonesterified fatty acids and b-hydroxybutyrate using
spectrophotometric methods (Wako). Statistical comparisons were performed
using Student’s t test.
SUPPLEMENTAL INFORMATION
Supplemental Information includes two tables, one figure, Supplemental
Experimental Procedures, and Supplemental References and can be found
with this article online at doi:10.1016/j.cmet.2010.02.001.
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